Popular Articles
Cellulite Cream

United States FDA Clears The REGEN Trial To Test Bioheart's Combination Gene And Stem Cell Therapy In Heart Failure Patients
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced today that the US FDA cleared a phase I clinical trial for MyoCell SDF-1 (Stromal Derived Factor - 1) to treat congestive heart failure. The REGEN trial will enroll 15 patients in a multicenter, randomized, dose escalation study to assess the safety and cardiovascular effects of the implantation of MyoCell SDF-1 in congestive heart failure patients post myocardial infarction(s).
generic viagra online
Human Genome Sciences Submits Biologics License Application To FDA For ABthrax(TM)
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its human monoclonal antibody drug ABthrax(TM) (raxibacumab) for the treatment of inhalation anthrax.
News of the day
Quark Pharmaceuticals Announces Data Indicating Potential Utility Of QPI-1007 For Treatment Of Glaucoma
Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, announced data suggesting that QPI-1007 prevents progressive retinal ganglion cell (RGC) loss in an increased ocular pressure (IOP) rat model of glaucoma. The experiments performed by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal, indicate that QPI-1007 has the potential to treat patients with glaucoma. QPI-1007 is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases.
Medical Devices

HHS Rescinds Controversial Medicaid Regulations

The Health and Human Services Department Monday "rescinded three controversial Bush administration regulations governing Medicaid and said it would postpone and possibly change or rescind a fourth," according to CQ Politics. Democrats had been particularly critical of the regulations, which had upset health care providers, state governments and advocates for the poor, and the decision to rescind them was not unexpected. CQ Politics reports: "Critics charged that the [Bush] administration was trying to shift to the states, from the federal government, the burden for about $19.6 billion in Medicaid spending over five years. Medicaid, a health insurance entitlement program for the poor, is a shared federal-state program, and there is constant tension between the two over costs" (Wayne, 6/29). Modern Healthcare also reports: "Specifically, the Obama administration will be rescinding all or part of three Medicaid regulations that were previously issued. The rulemakings in total would have eliminated reimbursement for school-based administrative and transportation costs; limited the outpatient hospital and clinic service benefit for Medicaid; and restricted beneficiary access to case management services. The CMS also plans to delay until June 30, 2010, parts of a regulation that clarified limitations on healthcare-related tax programs, to determine whether states need additional clarification or guidance. A moratorium for most of the regulations had been set to expire on July 1, under a provision set by the American Recovery and Reinvestment Act of 2009" (Lubell, 6/29). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):